[go: up one dir, main page]

CN105646616A - Stevia glucoside B crystal form G as well as preparation method, food composition and application thereof - Google Patents

Stevia glucoside B crystal form G as well as preparation method, food composition and application thereof Download PDF

Info

Publication number
CN105646616A
CN105646616A CN201610173788.5A CN201610173788A CN105646616A CN 105646616 A CN105646616 A CN 105646616A CN 201610173788 A CN201610173788 A CN 201610173788A CN 105646616 A CN105646616 A CN 105646616A
Authority
CN
China
Prior art keywords
stevioside
crystal formation
crystal form
glycosides
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201610173788.5A
Other languages
Chinese (zh)
Other versions
CN105646616B (en
Inventor
朱理平
梅雪锋
黄颖
王建荣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ZHUCHENG HAOTIAN PHARM CO Ltd
Original Assignee
ZHUCHENG HAOTIAN PHARM CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ZHUCHENG HAOTIAN PHARM CO Ltd filed Critical ZHUCHENG HAOTIAN PHARM CO Ltd
Priority to CN201610173788.5A priority Critical patent/CN105646616B/en
Publication of CN105646616A publication Critical patent/CN105646616A/en
Priority to PCT/CN2017/074115 priority patent/WO2017161985A1/en
Application granted granted Critical
Publication of CN105646616B publication Critical patent/CN105646616B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/24Condensed ring systems having three or more rings
    • C07H15/256Polyterpene radicals
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52Adding ingredients
    • A23L2/60Sweeteners
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Saccharide Compounds (AREA)

Abstract

本发明属于甜味剂技术领域,尤其涉及一种甜菊糖B苷晶型G、其制备方法、食品组合物及应用,所述甜菊糖B苷晶型G使用Cu-Kα射线测量得到的X-射线粉末衍射分析,以度表示的2θ值至少在3.93,13.45,16.62,18.33,19.90,23.95和28.02处有明显的特征衍射峰。本发明运用XRPD、DSC、TGA、DVS等固体化学分析手段对所述晶型G进行了全面表征,发现所述晶型G具有结晶度高,稳定性好、水溶性好、吸湿性小等优点,适于更加广泛的运用领域。本发明涉及的制备方法简单,易于操作,选择性多,重现性好,可以稳定地获得目标晶型。

The present invention belongs to the technical field of sweeteners, and in particular relates to stevioside B crystal form G, its preparation method, food composition and application. The stevioside B glycoside crystal form G is X- According to X-ray powder diffraction analysis, the 2θ values expressed in degrees have obvious characteristic diffraction peaks at least at 3.93, 13.45, 16.62, 18.33, 19.90, 23.95 and 28.02. The present invention uses XRPD, DSC, TGA, DVS and other solid chemical analysis methods to comprehensively characterize the crystal form G, and finds that the crystal form G has the advantages of high crystallinity, good stability, good water solubility, and low hygroscopicity. , suitable for a wider range of applications. The preparation method involved in the invention is simple, easy to operate, has many selectivities and good reproducibility, and can stably obtain the target crystal form.

Description

甜菊糖B苷晶型G、其制备方法、食品组合物及应用Steviol glycoside B crystal form G, its preparation method, food composition and application

技术领域technical field

本发明属于甜味剂技术领域,尤其涉及一种甜菊糖B苷晶型G、其制备方法、食品组合物及应用。The invention belongs to the technical field of sweeteners, and in particular relates to steviol glycoside B crystal form G, its preparation method, food composition and application.

背景技术Background technique

甜叶菊是一种小菊科植物,原产于南美巴拉圭与巴西接壤的阿曼拜山脉。现已确定的甜叶菊甜味成分有9种:甜菊苷、甜菊双糖苷、甜菊糖A苷-甜菊糖F苷和杜克苷G。它们均属苷类化合物,具有相同苷元—甜菊醇(steviol);区别仅在于苷键上结合糖的种类、数量和构型。因为它们都是带有甜味的苷类化合物,统称为甜菊糖(SteviolGlycosides)。其中,甜菊糖B苷是一种甜度约为蔗糖150倍的甜菊糖苷类化合物。甜菊糖B苷(RebGudiosideB,RB),其结构式如下所示:Stevia is a small Compositae plant native to the Amambai Mountains on the border between Paraguay and Brazil in South America. There are 9 identified sweet components of stevia: stevioside, steviobioside, stevioside A-stevioside F and dulcoside G. They all belong to glycoside compounds and have the same aglycone-steviol; the difference is only in the type, quantity and configuration of the sugar bound on the glycoside bond. Because they are all glycosides with sweet taste, they are collectively called Steviol Glycosides. Among them, stevioside B is a stevioside compound with a sweetness about 150 times that of sucrose. Stevioside B (RebGudiosideB, RB), its structural formula is as follows:

在甜叶菊提取物中,甜菊糖G苷作为甜味剂已经被广泛用于饮料、食品和保健品中。但是,甜菊糖G苷带有天然的轻微苦味或青草味,现有技术还无法完全去除或者掩盖,这使得饮料和食品行业还不敢轻易地完全用甜菊糖来简单替代白糖。在杂志《JournGlofGgriculturGlGndFoodChemistry》中的一篇名为“HumGnPsychometricGndTGsteReceptorResponsestoSteviolGlycosides”中的研究表明,甜菊糖B苷相对于甜菊糖G苷,其甜度差不多,但是苦味要略弱。所以,甜菊糖B苷具有优于甜菊糖G苷的口感,而可以作为甜味剂使用。专利CN104602543G报道了甜菊糖B苷与其他糖的组合物在食品及饮料应用。由于在甜菊叶中的含量较低,所以目前甜菊糖B苷的制备方法主要是通过氢氧化钠水解甜菊糖G苷得到。在室温条件下甜菊糖B苷的水溶性极低,从而限制了其使用。Among stevia extracts, steviol glycosides have been widely used in beverages, foods and health products as sweeteners. However, stevioside G has a natural slight bitterness or grassy taste, which cannot be completely removed or covered up in the prior art, which makes the beverage and food industries dare not to simply replace white sugar with stevioside completely. A study in the journal "JournGlofGgriculturGlGndFoodChemistry" titled "HumGnPsychometricGndTGsteReceptorResponsestoSteviolGlycosides" shows that steviol glycoside B has similar sweetness to steviol glycoside G, but the bitterness is slightly weaker. Therefore, stevioside B has a better taste than stevioside G, and can be used as a sweetener. Patent CN104602543G reports the application of stevioside B glycosides and other sugars in food and beverages. Due to the low content in stevia leaves, the current preparation method of stevioside B is mainly obtained by hydrolyzing stevioside G with sodium hydroxide. Stevioside B has very low water solubility at room temperature, which limits its use.

同一化合物的不同晶型在溶解度、溶出速率、熔点、外观及生物有效性等方面有显著差异,从而影响其稳定性和生物利用度。药物多晶型现象的研究已经成为制药工艺及新药制剂确定前必不可少的重要部分。对于甜菊糖B苷来说,对其进行多晶型研究也是至关重要的。专利US20130267693G1中报道了甜菊糖B苷晶型1、晶型2、晶型3、晶型4及其制备方法。但从X-射线粉末衍射图谱及偏光照片来看,该四种晶型结晶度差并含有部分无定形。对于吸湿性高的糖苷类化合物来说,产品中的无定形可能导致在储存及运输过程中吸湿结块结团。同时,该四种晶型并未改善甜菊糖B苷的水溶性。Different crystal forms of the same compound have significant differences in solubility, dissolution rate, melting point, appearance and bioavailability, which affect its stability and bioavailability. The study of drug polymorphism has become an indispensable and important part of the pharmaceutical process and the determination of new drug preparations. For stevioside B, polymorphic research is also crucial. Patent US20130267693G1 reports steviol glycoside B crystal form 1, crystal form 2, crystal form 3, crystal form 4 and their preparation methods. However, from the X-ray powder diffraction patterns and polarized light photos, the four crystal forms have poor crystallinity and contain some amorphous forms. For highly hygroscopic glycosides, the amorphous state in the product may lead to hygroscopic agglomeration during storage and transportation. At the same time, the four crystal forms did not improve the water solubility of stevioside B.

本领域迫切需要提供一种性能更好的晶型,例如结晶度高、水溶性好、吸湿性小、稳定性高的新晶型。同时,迫切需要提供上述晶型的制备方法和用途。There is an urgent need in this field to provide a crystal form with better performance, such as a new crystal form with high crystallinity, good water solubility, low hygroscopicity, and high stability. At the same time, there is an urgent need to provide the preparation method and application of the above-mentioned crystal form.

发明内容Contents of the invention

本发明的目的之一在于:提供一种结晶度高、水溶性好、稳定性高、吸湿性小的甜菊糖B苷晶型G。One of the objectives of the present invention is to provide stevioside B crystal form G with high crystallinity, good water solubility, high stability and low hygroscopicity.

为解决上述技术问题,本发明的技术方案是:In order to solve the problems of the technologies described above, the technical solution of the present invention is:

甜菊糖B苷晶型G,所述晶型G使用Cu-Kα射线测得的X-射线粉末衍射分析,以度表示的2θ角至少在3.93,13.45,16.62,18.33,19.90,23.95和28.02处有明显的特征衍射峰。Steviol glycoside crystalline form G, said crystalline form G is analyzed by X-ray powder diffraction using Cu-Kα radiation, and the 2θ angle expressed in degrees is at least 3.93, 13.45, 16.62, 18.33, 19.90, 23.95 and 28.02 There are obvious characteristic diffraction peaks.

作为一种改进,所述晶型G使用Cu-Kα射线测量得到的X-射线粉末衍射分析,以度表示的2θ值、误差范围为±1°,以表示的晶面间距d和以百分数表示的衍射峰的相对强度具有如下特征:As an improvement, the X-ray powder diffraction analysis of the crystal form G using Cu-Kα ray measurement, the 2θ value expressed in degrees, the error range is ±1°, in order The interplanar spacing d expressed and the relative intensity of the diffraction peaks expressed as a percentage have the following characteristics:

dd 相对强度%Relative Strength% 3.933.93 22.4422.44 100.0100.0 7.887.88 11.2211.22 5.65.6 9.059.05 9.769.76 4.94.9 9.259.25 9.559.55 5.05.0 10.8310.83 8.168.16 5.35.3 12.0212.02 7.367.36 3.53.5 13.4513.45 6.586.58 23.823.8 13.8113.81 6.416.41 4.84.8 14.3614.36 6.166.16 3.83.8 14.9814.98 5.915.91 6.06.0 16.3116.31 5.435.43 4.24.2 16.6216.62 5.335.33 21.421.4 17.3817.38 5.105.10 5.45.4 18.3318.33 4.844.84 23.723.7 18.6218.62 4.764.76 4.94.9 19.9019.90 4.464.46 22.722.7 20.1120.11 4.414.41 9.49.4 22.9422.94 3.873.87 7.42 -->7.42 --> 23.9523.95 3.713.71 12.812.8 24.3224.32 3.663.66 4.24.2 27.5627.56 3.233.23 5.45.4 28.0228.02 3.183.18 13.813.8

.

作为一种改进,所述晶型G的差示扫描量热分析在60-140℃、150-180℃和200-240℃有明显吸热峰。As an improvement, the differential scanning calorimetry analysis of the crystal form G has obvious endothermic peaks at 60-140°C, 150-180°C and 200-240°C.

作为一种改进,所述晶型G的热失重分析在270±10℃开始分解。As an improvement, the thermogravimetric analysis of the crystal form G starts to decompose at 270±10°C.

作为一种改进,所述晶型G有如图4所示的动态水分吸附(DVS)图谱,在相对湿度为0-45%范围内,其吸收水分的质量百分数在0-2.5%,在相对湿度为45-55%范围内,其吸收水分的质量百分数在2.5-5.1%,在相对湿度55%以上,其吸收水分的质量百分数波动范围较小。As an improvement, the crystalline form G has a dynamic moisture adsorption (DVS) spectrum as shown in Figure 4, in the range of 0-45% relative humidity, the mass percentage of absorbed moisture is 0-2.5%, and the relative humidity is 0-2.5%. In the range of 45-55%, the mass percentage of water absorption is 2.5-5.1%, and the fluctuation range of the mass percentage of water absorption is small when the relative humidity is above 55%.

作为一种改进,所述晶型G有如图5所示形貌特征。As an improvement, the crystal form G has the morphological characteristics as shown in FIG. 5 .

本发明的目的之二在于:提供一种工艺简单、易于操作、稳定性高和流动性好的甜菊糖B苷晶型G的制备方法。The second object of the present invention is to provide a method for preparing stevioside B crystal form G with simple process, easy operation, high stability and good fluidity.

为解决上述技术问题,本发明的技术方案是:In order to solve the problems of the technologies described above, the technical solution of the present invention is:

甜菊糖B苷晶型G的制备方法,所述制备方法包括以下步骤:A preparation method of stevioside B crystal form G, the preparation method comprising the following steps:

(1)混悬:在0-100℃温度范围内,将甜菊糖B苷与溶剂混合0.1-48h,得到混悬溶液;(1) Suspension: within the temperature range of 0-100°C, mix stevioside B with a solvent for 0.1-48 hours to obtain a suspension solution;

(2)过滤:在0-100℃温度范围内,将混悬溶液过滤或离心,得到白色固体,即得甜菊糖B苷晶型G;(2) Filtration: within the temperature range of 0-100°C, filter or centrifuge the suspension solution to obtain a white solid, that is, stevioside B crystal form G;

(3)冷却:步骤(2)过滤或离心后的澄清溶液,冷却至0-50℃,析出白色固体,过滤,即得甜菊糖B苷晶型G;(3) Cooling: the clarified solution after filtering or centrifuging in step (2) is cooled to 0-50°C, a white solid is precipitated, and filtered to obtain Stevioside B crystal form G;

(4)挥发:步骤(2)过滤或离心后的澄清溶液,置于0-100℃温度范围内挥发,析出白色固体,即得甜菊糖B苷晶型G。(4) Volatilization: the clarified solution after filtration or centrifugation in step (2) is placed in the temperature range of 0-100°C to volatilize, and a white solid is precipitated to obtain stevioside B crystal form G.

作为一种改进,步骤(1)中,所述的甜菊糖B苷的干物质纯度为50-100%。As an improvement, in step (1), the dry matter purity of the stevioside B is 50-100%.

作为一种改进,所述溶剂为水、甲醇、乙醇、1-丙醇、2-丙醇、3-甲基-1-丁醇、2-甲基-1-丙醇、乙腈、丙酮、甲乙酮、甲基异丁酮、乙酸甲酯、甲酸乙酯、乙酸乙酯、乙酸丁酯、乙酸丙酯、乙酸异丙酯、乙酸异丁酯或三丁甲基乙醚中的一种或两种以上。As an improvement, the solvent is water, methanol, ethanol, 1-propanol, 2-propanol, 3-methyl-1-butanol, 2-methyl-1-propanol, acetonitrile, acetone, methyl ethyl ketone , methyl isobutyl ketone, methyl acetate, ethyl formate, ethyl acetate, butyl acetate, propyl acetate, isopropyl acetate, isobutyl acetate or tributylmethyl ether, or one or more of them.

本发明的目的之三在于:提供一种含有所述甜菊糖B苷晶型G的食品组合物。The third object of the present invention is to provide a food composition containing the steviol glycoside B crystal form G.

本发明的目的之四在于:提供所述甜菊糖B苷晶型G及其制备方法在食品、饮料及药品中的应用。The fourth object of the present invention is to provide the application of the stevioside B glycoside crystal form G and its preparation method in food, beverage and medicine.

由于采用了上述技术方案,本发明的有益效果是:Owing to adopted above-mentioned technical scheme, the beneficial effect of the present invention is:

本发明提供的甜菊糖B苷晶型G的制备方法,其工艺简单、易于操作、可通过多种方法制得甜菊糖B苷晶型G,且制得的产品结晶度高、吸湿性低、稳定性高、水溶性好。The preparation method of stevioside B crystal form G provided by the present invention has a simple process and is easy to operate, and stevioside B crystal form G can be prepared by various methods, and the obtained product has high crystallinity, low hygroscopicity, High stability and good water solubility.

附图说明Description of drawings

图1是本发明提供的甜菊糖B苷晶型G的X-射线粉末衍射(XRPD)图;Fig. 1 is the X-ray powder diffraction (XRPD) pattern of steviol glycoside B crystal form G provided by the present invention;

图2是本发明提供的甜菊糖B苷晶型G的差示扫描量热分析(DSC)图;Fig. 2 is the differential scanning calorimetry (DSC) diagram of stevioside B crystal form G provided by the present invention;

图3是本发明提供的甜菊糖B苷晶型G的热失重分析(TG)图;Fig. 3 is the thermogravimetric analysis (TG) diagram of stevioside B glycoside crystal form G provided by the present invention;

图4是本发明提供的甜菊糖B苷晶型G的动态水分吸附(DVS)图;Fig. 4 is the dynamic water adsorption (DVS) diagram of stevioside B crystal form G provided by the present invention;

图5是本发明提供的甜菊糖B苷晶型G的偏光照片;Fig. 5 is a polarized photo of stevioside B glycoside crystal form G provided by the present invention;

图6是本发明提供的甜菊糖B苷晶型G在干燥前后的X-射线粉末衍射(XRPD)比较图;Fig. 6 is a comparison diagram of X-ray powder diffraction (XRPD) before and after drying of stevioside B crystal form G provided by the present invention;

图7是本发明提供的甜菊糖B苷晶型G在40℃、湿度75%的条件下储存半年的X-射线粉末衍射(XRPD)比较图;Fig. 7 is a comparison chart of X-ray powder diffraction (XRPD) of stevioside B crystal form G stored at 40°C and humidity of 75% for half a year provided by the present invention;

图8是本发明提供的甜菊糖B苷晶型G在40℃、湿度75%的条件下储存半年的高效液相(HPLC)比较图。Fig. 8 is a comparison chart of high performance liquid phase (HPLC) of stevioside B crystalline form G provided by the present invention stored at 40°C and humidity of 75% for half a year.

具体实施方式detailed description

为了使本发明的目的、技术方案及优点更加清楚明白,以下结合附图及实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。In order to make the object, technical solution and advantages of the present invention clearer, the present invention will be further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described here are only used to explain the present invention, not to limit the present invention.

实施例一Embodiment one

在室温条件下,将20g物质纯度为100%的甜菊糖B苷加入100mL甲醇中,搅拌12h后,过滤,得到滤液和白色固体,滤液和白色固体分别于25℃下真空干燥,均得甜菊糖B苷晶型G。At room temperature, 20 g of stevioside B with a material purity of 100% was added to 100 mL of methanol, stirred for 12 hours, and then filtered to obtain a filtrate and a white solid, which were vacuum-dried at 25°C to obtain stevioside Beta glycoside crystal form G.

实施例二Embodiment two

在50℃条件下,将20g物质纯度为100%的甜菊糖B苷加入100mL甲醇中,搅拌12h后,过滤,得到滤液和白色固体,滤液和白色固体分别于25℃下真空干燥,均得甜菊糖B苷晶型G。At 50°C, add 20g of stevioside B with a material purity of 100% into 100mL of methanol, stir for 12 hours, and filter to obtain a filtrate and a white solid, which are vacuum-dried at 25°C to obtain stevia Sugar B glycoside crystal form G.

实施例三Embodiment three

在室温条件下,将40g物质纯度为50%的甜菊糖B苷加入100mL甲醇中,搅拌12h后,过滤得到滤液和白色固体,滤液和白色固体分别于25℃下真空干燥,均得甜菊糖B苷晶型G。At room temperature, 40 g of stevioside B with a material purity of 50% was added to 100 mL of methanol, stirred for 12 hours, and filtered to obtain a filtrate and a white solid. The filtrate and the white solid were vacuum-dried at 25° C. respectively to obtain stevioside B. Glycoside crystal form G.

实施例四Embodiment Four

在室温条件下,将20g物质纯度为100%的甜菊糖B苷加入70mL30%的甲醇-水(v/v)体系中,搅拌12h后,过滤,得到滤液和白色固体,滤液和白色固体分别于25℃下真空干燥,均得甜菊糖B苷晶型G。At room temperature, 20 g of stevioside B with a material purity of 100% was added to 70 mL of 30% methanol-water (v/v) system, stirred for 12 hours, and filtered to obtain a filtrate and a white solid, which were respectively in Vacuum drying at 25°C yielded steviol glycoside B crystalline form G.

实施例五Embodiment five

在室温条件下,将20g物质纯度为100%的甜菊糖B苷加入50mL50%的甲醇-水(v/v)体系中,搅拌12h后,过滤,得到滤液和白色固体,滤液和白色固体分别于25℃下真空干燥,均得甜菊糖B苷晶型G。At room temperature, 20 g of stevioside B with a material purity of 100% was added to 50 mL of 50% methanol-water (v/v) system, stirred for 12 hours, and then filtered to obtain a filtrate and a white solid, which were respectively in Vacuum drying at 25°C yielded steviol glycoside B crystalline form G.

实施例六Embodiment six

在室温条件下,将20g物质纯度为100%的甜菊糖B苷加入50mL50%的乙醇-水(v/v)体系中,搅拌12h后,过滤,得到滤液和白色固体,滤液和白色固体分别于25℃下真空干燥,均得甜菊糖B苷晶型G。At room temperature, 20 g of stevioside B with a material purity of 100% was added to 50 mL of 50% ethanol-water (v/v) system, stirred for 12 hours, and then filtered to obtain a filtrate and a white solid, which were respectively in Vacuum drying at 25°C yielded steviol glycoside B crystalline form G.

实施例七Embodiment seven

在室温条件下,将20g物质纯度为100%的甜菊糖B苷加入50mL50%的乙醇-水(v/v)体系中,搅拌48h后,过滤,得到滤液和白色固体,滤液和白色固体分别于25℃下真空干燥,均得甜菊糖B苷晶型G。At room temperature, 20 g of stevioside B with a material purity of 100% was added to 50 mL of 50% ethanol-water (v/v) system, stirred for 48 hours, and filtered to obtain a filtrate and a white solid, which were respectively in Vacuum drying at 25°C yielded steviol glycoside B crystalline form G.

实施例八Embodiment Eight

在室温条件下,将20g物质纯度为100%的甜菊糖B苷加入50mL50%的乙醇-水(v/v)体系中,搅拌48h后,过滤,得到滤液和白色固体,滤液和白色固体分别于50℃下真空干燥,均得甜菊糖B苷晶型G。At room temperature, 20 g of stevioside B with a material purity of 100% was added to 50 mL of 50% ethanol-water (v/v) system, stirred for 48 hours, and filtered to obtain a filtrate and a white solid, which were respectively in Vacuum drying at 50°C yielded steviol glycoside B crystalline form G.

实施例九Embodiment nine

在室温条件下,将20g物质纯度为100%的甜菊糖B苷加入200mL50%的乙醇-水(v/v)体系中,搅拌48h后,过滤得到的滤液快速冷却至5℃,析出大量晶体,过滤,晶体干燥,得甜菊糖B苷晶型G。At room temperature, 20 g of stevioside B with a material purity of 100% was added to 200 mL of 50% ethanol-water (v/v) system, and after stirring for 48 hours, the filtrate obtained by filtration was rapidly cooled to 5° C., and a large amount of crystals were precipitated. Filter and dry the crystals to obtain steviol glycoside B crystalline form G.

实施例十Embodiment ten

在90℃条件下,将20g物质纯度为100%的甜菊糖B苷加入100mL50%的乙醇-水(v/v)体系中,搅拌48h后,过滤得到的滤液快速冷却至室温,析出大量晶体,过滤,晶体干燥,得甜菊糖B苷晶型G。At 90°C, 20 g of stevioside B with a material purity of 100% was added to 100 mL of 50% ethanol-water (v/v) system, stirred for 48 hours, and the filtrate obtained by filtering was rapidly cooled to room temperature, and a large amount of crystals were precipitated. Filter and dry the crystals to obtain steviol glycoside B crystalline form G.

实施例十一Embodiment Eleven

在90℃条件下,将20g物质纯度为100%的甜菊糖B苷加入100mL50%的乙醇-水(v/v)体系中,搅拌48h后,过滤得到的滤液以1℃/h的降温速率冷却至室温,析出大量晶体,过滤,晶体干燥,得甜菊糖B苷晶型G。At 90°C, add 20g of stevioside B with a material purity of 100% into 100mL of 50% ethanol-water (v/v) system, stir for 48 hours, and then filter the filtrate to cool at a cooling rate of 1°C/h After reaching room temperature, a large amount of crystals precipitated, filtered, and the crystals were dried to obtain stevioside B crystalline form G.

实施例十二Embodiment 12

在90℃条件下,将20g物质纯度为100%的甜菊糖B苷加入100mL50%的乙醇-水(v/v)体系中,搅拌48h后,过滤得到的滤液以10℃/h的降温速率冷却至室温,并在室温条件下静置2h,析出大量晶体,过滤,晶体干燥,得甜菊糖B苷晶型G。At 90°C, add 20g of stevioside B with a material purity of 100% to 100mL of 50% ethanol-water (v/v) system, stir for 48 hours, and then filter the filtrate to cool at a cooling rate of 10°C/h to room temperature, and stood at room temperature for 2 hours, a large amount of crystals were precipitated, filtered, and the crystals were dried to obtain stevioside B crystalline form G.

实施例十三Embodiment Thirteen

在90℃条件下,将20g物质纯度为100%的甜菊糖B苷加入100mL50%的乙醇-水(v/v)体系中,搅拌48h后,过滤得到的滤液在室温条件下敞口自然挥发,待析出大量晶体,过滤,晶体干燥,得甜菊糖B苷晶型G。At 90°C, 20 g of steviol glycosides with a material purity of 100% were added to 100 mL of 50% ethanol-water (v/v) system, stirred for 48 hours, and the filtrate obtained by filtering was left open to volatilize naturally at room temperature. After a large amount of crystals are precipitated, filter and dry the crystals to obtain steviol glycoside B crystal form G.

实施例十四Embodiment Fourteen

在90℃条件下,将20g物质纯度为100%的甜菊糖B苷加入100mL50%的乙醇-水(v/v)体系中,搅拌48h后,过滤得到的滤液在室温、氮气流量为25mL/min条件下挥发,待析出大量晶体,过滤,晶体干燥,得甜菊糖B苷晶型G。At 90°C, add 20 g of stevioside B with a material purity of 100% to 100 mL of 50% ethanol-water (v/v) system, stir for 48 hours, and filter the filtrate at room temperature with a nitrogen flow rate of 25 mL/min Volatilize under conditions, and after a large amount of crystals are precipitated, filter and dry the crystals to obtain stevioside B crystalline form G.

实施例十五Embodiment fifteen

在90℃条件下,将20g物质纯度为100%的甜菊糖B苷加入100mL50%的乙醇-水(v/v)体系中,搅拌48h后,过滤得到的滤液在室温、真空度为0.05MPa条件下挥发,待析出大量晶体,过滤,晶体干燥,得甜菊糖B苷晶型G。At 90°C, add 20 g of steviol glycosides with a material purity of 100% into 100 mL of 50% ethanol-water (v/v) system, stir for 48 hours, and filter the filtrate at room temperature and a vacuum of 0.05 MPa Volatilize under high temperature, after a large amount of crystals are precipitated, filter, and dry the crystals to obtain stevioside B crystalline form G.

实施例十六Embodiment sixteen

在90℃条件下,将20g物质纯度为100%的甜菊糖B苷加入100mL50%的乙醇-水(v/v)体系中,搅拌48h后,过滤得到的滤液在室温、真空度为0.05MPa条件下挥发,待析出大量晶体,过滤,晶体干燥,得甜菊糖B苷晶型G。At 90°C, add 20 g of steviol glycosides with a material purity of 100% into 100 mL of 50% ethanol-water (v/v) system, stir for 48 hours, and filter the filtrate at room temperature and a vacuum of 0.05 MPa Volatilize under high temperature, after a large amount of crystals are precipitated, filter, and dry the crystals to obtain stevioside B crystalline form G.

实施例十七Embodiment 17

在0℃条件下,将20g物质纯度为100%的甜菊糖B苷加入100mL甲醇中,搅拌48h后,过滤,得到滤液和白色固体,滤液和白色固体分别于25℃下真空干燥,均得甜菊糖B苷晶型G。At 0°C, add 20g of stevioside B with a material purity of 100% into 100mL of methanol, stir for 48 hours, and filter to obtain a filtrate and a white solid, which are vacuum-dried at 25°C to obtain stevia Sugar B glycoside crystal form G.

实施例十八Embodiment eighteen

在100℃条件下,将20g物质纯度为100%的甜菊糖B苷加入50mL50%的乙醇-水(v/v)体系中,搅拌0.1h后,过滤,得到滤液和白色固体,滤液和白色固体分别于25℃下真空干燥,均得甜菊糖B苷晶型G。At 100°C, add 20 g of stevioside B with a material purity of 100% into 50 mL of 50% ethanol-water (v/v) system, stir for 0.1 h, and filter to obtain a filtrate and a white solid, a filtrate and a white solid Vacuum-dried at 25°C respectively to obtain stevioside B crystalline form G.

对上述实施例制得的甜菊糖B苷钠盐晶型G进行X-射线粉末衍射分析(XRPD)、差示扫描量热分析(DSC)、热失重分析(TG)、动态水分吸附分析(DVS)等。Carry out X-ray powder diffraction analysis (XRPD), differential scanning calorimetry (DSC), thermogravimetric analysis (TG), dynamic water adsorption analysis (DVS) to the stevioside B glycoside sodium salt crystalline form G that above-mentioned embodiment makes )Wait.

XRPD分析:其采用德国布鲁克仪器有限公司BrukerD8GdvGnce型的衍射仪于室温进行检测,采用Cu–Kα射线2θ角扫描从3度到40度,扫描速度为0.2度/秒。其分析结果见图1,XRPD谱图显示上述实施例制得的甜菊糖B苷晶型G具有良好的结晶度。XRPD analysis: it was detected at room temperature by a Bruker D8GdvGnce diffractometer from Bruker Instruments Co., Ltd., Germany, using Cu–Kα rays The 2θ angle scans from 3 degrees to 40 degrees, and the scanning speed is 0.2 degrees/second. The analysis results are shown in Figure 1, and the XRPD spectrum shows that the stevioside B crystal form G prepared in the above example has good crystallinity.

在样品粉末X-射线粉末衍射图谱中,由特定晶型得到的衍射谱图往往是特征性的。因为结晶条件、粒径、混合物的相对含量和其它测试条件的差异,衍射谱图可能会产生择优取向效果,从而导致谱图中某些谱带(尤其是在低角度)的相对强度发生变化。因此,衍射峰的相对强度对所针对的晶体并非是特征性的,判断是否与已知的晶型相同时,更应该注意的是峰的位置而不是它们的相对强度。另外,判断晶型是否一样时应注意保持整体观念,因为并不是一条衍射线代表一个物相,而是一套特定的“d-I/I1”数据才代表某一物相。还应指出的是,在混合物的鉴定中,由于含量下降等因素会造成部分衍射线的缺失,此时,无需依赖高纯试样中观察到的全部谱带,甚至一条谱带也可能对给定的晶体是特征性的。In the sample powder X-ray powder diffraction pattern, the diffraction pattern obtained from a specific crystal form is often characteristic. Because of differences in crystallization conditions, particle size, relative amounts of mixtures, and other test conditions, diffraction patterns may have preferential orientation effects, resulting in changes in the relative intensities of certain bands (especially at low angles) in the pattern. Therefore, the relative intensities of the diffraction peaks are not characteristic of the crystal in question, and when judging whether it is the same as a known crystal form, more attention should be paid to the positions of the peaks rather than their relative intensities. In addition, when judging whether the crystal form is the same, you should pay attention to maintaining the overall concept, because not a diffraction line represents a phase, but a specific set of "d-I/I1" data represents a certain phase. It should also be pointed out that in the identification of mixtures, due to factors such as content decline, some diffraction lines will be missing. At this time, it is not necessary to rely on all the bands observed in the high-purity sample, and even one band may affect the given Certain crystals are characteristic.

DSC分析:其采用美国铂金埃尔默公司的DSC8500型差示扫描量热仪进行检测,气氛为氮气,加热速度为10摄氏度/分钟。其分析结果见图2。DSC analysis: it adopts the DSC8500 differential scanning calorimeter of American Platinum Elmer Company to detect, the atmosphere is nitrogen, and the heating rate is 10 degrees Celsius/minute. The analysis results are shown in Figure 2.

TG分析:其采用德国耐驰公司的NetzschTG209F3型热重分析仪检测,温度范围:30-400℃,扫描速率:10K/min,吹扫气:25mL/min。其分析结果见图3。TG analysis: It is detected by Netzsch TG209F3 thermogravimetric analyzer of German NETZSCH company, temperature range: 30-400°C, scan rate: 10K/min, purge gas: 25mL/min. The analysis results are shown in Figure 3.

DVS分析:其采用英国SMS仪器公司DVSIntrinsic型动态水分吸附仪进行测定,测定温度:25℃;相对湿度:0-95%。其分析结果见图4。DVS analysis: It is measured by DVSIntrinsic dynamic moisture adsorption instrument of British SMS Instrument Company, measuring temperature: 25°C; relative humidity: 0-95%. The analysis results are shown in Figure 4.

偏光照片:其采用上海长方光学仪器有限公司的XPV-400E偏光显微镜进行实验,测试放大倍数:5倍。其分析结果见图5。偏光照片显示,上述实施例制得的甜菊糖B苷晶型G为菱型晶体,具有良好的形貌特征。Polarized photo: The XPV-400E polarized microscope of Shanghai Changfang Optical Instrument Co., Ltd. was used for the experiment, and the test magnification: 5 times. The analysis results are shown in Figure 5. Polarized photos show that the steviol glycoside B crystal form G prepared in the above example is a rhombohedral crystal with good morphology.

对上述实施例制得的甜菊糖B苷晶型G,在干燥后进行XRPD分析,其分析结果见图6。从图6中可以看出其晶型不变,晶型稳定性好。The stevioside B glycoside crystal form G prepared in the above example was subjected to XRPD analysis after drying, and the analysis results are shown in FIG. 6 . It can be seen from Figure 6 that the crystal form remains unchanged and the crystal form is stable.

对上述实施例制得的甜菊糖B苷晶型G,在40℃、RH75%条件下储存半年,其分析结果见图7。从图7中可以看出其晶型不变,说明该晶型在高湿条件下物理稳定性好。The steviol glycoside B crystal form G prepared in the above example was stored for half a year at 40° C. and RH 75%, and the analysis results are shown in FIG. 7 . It can be seen from Figure 7 that the crystal form remains unchanged, indicating that the crystal form has good physical stability under high humidity conditions.

HPLC分析:其采用美国安捷伦科技有限公司的1260infinity液相色谱仪测定。样品溶液配制方法:精确称量25-50毫克甜菊糖B苷晶型G样品,放入25毫升的容量瓶中,然后加入水-乙腈(7:3,v/v)溶液,进行溶解并定容至刻度。磷酸钠缓冲液(规格:10mmol/L,pH值:2.6)的配置方法:将2.76克磷酸二氢钠溶解到2升水中,加入磷酸,将pH值调至2.6。色谱柱:Phenomenex公司的LunG5μC18(2)100A型色谱柱。进样量:5μl。流速:1.0mL/min。柱温:40℃。检测器:210nm紫外检测。流动相:乙腈和磷酸钠缓冲液(规格:10mmol/L,pH值:2.6)的比例为32:68。分析结果见图8,上述实施例制得的甜菊糖B苷晶型G,具有好的化学稳定性,HPLC分析显示在40℃、RH75%条件下储存半年后,其纯度仍高达98.3%,说明该晶型在高湿条件下化学稳定性好。HPLC analysis: it is determined by 1260infinity liquid chromatograph of Agilent Technologies Co., Ltd., USA. Sample solution preparation method: accurately weigh 25-50 mg stevioside B crystal form G sample, put it into a 25 ml volumetric flask, then add water-acetonitrile (7:3, v/v) solution to dissolve and determine To the scale. Sodium phosphate buffer solution (specification: 10mmol/L, pH value: 2.6): Dissolve 2.76 grams of sodium dihydrogen phosphate in 2 liters of water, add phosphoric acid, and adjust the pH value to 2.6. Chromatographic column: Lun G5μC18(2)100A type chromatographic column of Phenomenex Company. Injection volume: 5 μl. Flow rate: 1.0 mL/min. Column temperature: 40°C. Detector: 210nm UV detection. Mobile phase: the ratio of acetonitrile and sodium phosphate buffer (specification: 10mmol/L, pH: 2.6) is 32:68. The analysis results are shown in Figure 8. The stevioside B crystal form G prepared in the above example has good chemical stability. HPLC analysis shows that after half a year of storage at 40°C and RH75%, its purity is still as high as 98.3%, indicating that The crystal form has good chemical stability under high humidity conditions.

上述实施例制得的甜菊糖B苷晶型G,具有很好的重现性。并且水溶性高并且稳定,约为0.5mg/mL,明显高于US20130267693A1中报道的晶型1-4。其分析结果如下表1:The steviol glycoside B crystalline form G prepared in the above examples has good reproducibility. And the water solubility is high and stable, about 0.5mg/mL, which is obviously higher than the crystal forms 1-4 reported in US20130267693A1. Its analysis result is as follows table 1:

表1Table 1

样品名称sample name 水中平衡溶解度(mg/mL)Equilibrium solubility in water (mg/mL) 实施例1甜菊糖B苷晶型GEmbodiment 1 Stevioside B glycoside crystal form G 0.4520.452 US 20130267693A1中晶型1Form 1 in US 20130267693A1 0.2910.291 US 20130267693A1中晶型2Form 2 in US 20130267693A1 0.2050.205 US 20130267693A1中晶型3Form 3 in US 20130267693A1 0.1600.160 US 20130267693A1中晶型4Form 4 in US 20130267693A1 0.0970.097

对上述实施例制得的甜菊糖B苷晶型G,在常规储存条件(45-80%RH)下略有吸湿性。甜菊糖B苷晶型G的吸湿性明显低于US20130267693A1中报道的晶型1-4,不易吸湿结块。分析结果如下表2:The stevioside B crystalline form G prepared in the above examples is slightly hygroscopic under normal storage conditions (45-80% RH). The hygroscopicity of stevioside B glycoside crystal form G is significantly lower than that of crystal forms 1-4 reported in US20130267693A1, and it is not easy to absorb moisture and agglomerate. The analysis results are shown in Table 2 below:

表2Table 2

上述实施例中所用的甜菊糖B苷原料由山东诸城浩天药业有限公司提供。The stevioside B glycoside raw materials used in the above examples were provided by Shandong Zhucheng Haotian Pharmaceutical Co., Ltd.

本发明提供的甜菊糖B苷晶型G可作为甜味剂应用于食品、饮料及药品中。The stevioside B crystal form G provided by the invention can be used as a sweetener in food, beverage and medicine.

本发明提供的甜菊糖B苷晶型G的制备方法可应用于食品、饮料及药品的制备工艺中。The preparation method of stevioside B crystal form G provided by the present invention can be applied in the preparation process of food, beverage and medicine.

以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等,均应包含在本发明的保护范围之内。The above descriptions are only preferred embodiments of the present invention, and are not intended to limit the present invention. Any modifications, equivalent replacements and improvements made within the spirit and principles of the present invention should be included in the protection of the present invention. within range.

Claims (8)

1. stevioside B glycosides crystal formation G, it is characterised in that described crystal formation G uses the X-ray powder diffraction analysis that Cu-K alpha ray records, to spend the 2 �� angles represented at least 3.93,13.45,16.62,18.33, there is obvious characteristic diffraction peak at 19.90,23.95 and 28.02 places.
2. stevioside B glycosides crystal formation G as claimed in claim 1, it is characterised in that described crystal formation G uses the X-ray powder diffraction analysis that Cu-K alpha ray measurements obtains, with spend represent 2 �� values, range of error for �� 1 ��, withThe relative intensity of the interplanar distance d represented and the diffraction maximum being expressed as a percentage has the feature that
2�� d Relative intensity % 3.93 22.44 100.0 7.88 11.22 5.6 9.05 9.76 4.9 9.25 9.55 5.0 10.83 8.16 5.3 12.02 7.36 3.5 13.45 6.58 23.8 13.81 6.41 4.8 14.36 6.16 3.8 14.98 5.91 6.0 16.31 5.43 4.2 16.62 5.33 21.4 17.38 5.10 5.4 18.33 4.84 23.7 18.62 4.76 4.9 19.90 4.46 22.7 20.11 4.41 9.4 22.94 3.87 7.4 23.95 3.71 12.8 24.32 3.66 4.2 27.56 3.23 5.4 28.02 3.18 13.8
��
3. stevioside B glycosides crystal formation G as claimed in claim 1, it is characterised in that described crystal formation G has differential scanning calorimetric thermogram spectrum substantially as shown in Figure 2,3, 4, thermogravimetic analysis (TGA) collection of illustrative plates and dynamic water absorption collection of illustrative plates.
4. the preparation method of stevioside B glycosides crystal formation G, it is characterised in that described preparation method comprises the following steps:
(1) suspendible: in 0-100 DEG C of temperature range, by stevioside B glycosides and solvent mixing 0.1-48h, obtains suspension solution;
(2) filter: in 0-100 DEG C of temperature range, suspension solution is filtered or centrifugal, obtain white solid, obtain stevioside B glycosides crystal formation G;
(3) cooling: step (2) filtration or the settled solution after centrifugal, is cooled to 0-50 DEG C, precipitates out white solid, filter, obtain stevioside B glycosides crystal formation G;
(4) volatilization: step (2) filtration or the settled solution after centrifugal, is placed in 0-100 DEG C of temperature range and volatilizees, precipitate out white solid, obtain stevioside B glycosides crystal formation G.
5. the preparation method of stevioside B glycosides crystal formation G as claimed in claim 4, it is characterised in that in step (1), the dry purity of described stevioside B glycosides is 50-100%.
6. the preparation method of stevioside B glycosides crystal formation G as claimed in claim 4, it is characterized in that, in step (1), described solvent is one or more in water, methanol, ethanol, 1-propanol, 2-propanol, 3-methyl-1-butanol, 2-methyl isophthalic acid-propanol, acetonitrile, acetone, butanone, methylisobutylketone, methyl acetate, Ethyl formate, ethyl acetate, butyl acetate, propyl acetate, isopropyl acetate, isobutyl acetate or three fourth MEEs.
7. food compositions, it is characterised in that described food compositions contains the stevioside B glycosides crystal formation G described in any one of claim 1-3.
8. the stevioside B glycosides crystal formation G as described in any one of claim 1-3 and preparation method thereof application in food, beverage and medicine.
CN201610173788.5A 2016-03-24 2016-03-24 Steviol glycoside B crystal form G, its preparation method, food composition and application Active CN105646616B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201610173788.5A CN105646616B (en) 2016-03-24 2016-03-24 Steviol glycoside B crystal form G, its preparation method, food composition and application
PCT/CN2017/074115 WO2017161985A1 (en) 2016-03-24 2017-02-20 Crystal form of rebaudioside b and preparation process therefor and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610173788.5A CN105646616B (en) 2016-03-24 2016-03-24 Steviol glycoside B crystal form G, its preparation method, food composition and application

Publications (2)

Publication Number Publication Date
CN105646616A true CN105646616A (en) 2016-06-08
CN105646616B CN105646616B (en) 2019-08-06

Family

ID=56495485

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610173788.5A Active CN105646616B (en) 2016-03-24 2016-03-24 Steviol glycoside B crystal form G, its preparation method, food composition and application

Country Status (2)

Country Link
CN (1) CN105646616B (en)
WO (1) WO2017161985A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017161985A1 (en) * 2016-03-24 2017-09-28 诸城市浩天药业有限公司 Crystal form of rebaudioside b and preparation process therefor and use thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020125947A1 (en) * 2018-12-18 2020-06-25 Telefonaktiebolaget Lm Ericsson (Publ) Method and controller for managing a microwave network
US12430725B2 (en) 2022-05-13 2025-09-30 Adobe Inc. Object class inpainting in digital images utilizing class-specific inpainting neural networks

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52120170A (en) * 1976-04-02 1977-10-08 Toyo Sugar Refining Separating method of sweetening substance from stevia
US20130267693A1 (en) * 2010-12-13 2013-10-10 Cargill, Incorporated Crystalline forms of rebaudioside b
CN105037458A (en) * 2015-07-23 2015-11-11 诸城市浩天药业有限公司 Stevioside D glycoside crystal form A and preparation method and application thereof
CN105407739A (en) * 2013-07-31 2016-03-16 帝斯曼知识产权资产管理有限公司 Stable sweetener compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102093447B (en) * 2010-12-30 2015-04-08 青岛润浩甜菊糖高科有限公司 Purifying method of stevioside RB
CN105646616B (en) * 2016-03-24 2019-08-06 诸城市浩天药业有限公司 Steviol glycoside B crystal form G, its preparation method, food composition and application

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52120170A (en) * 1976-04-02 1977-10-08 Toyo Sugar Refining Separating method of sweetening substance from stevia
US20130267693A1 (en) * 2010-12-13 2013-10-10 Cargill, Incorporated Crystalline forms of rebaudioside b
CN105407739A (en) * 2013-07-31 2016-03-16 帝斯曼知识产权资产管理有限公司 Stable sweetener compositions
CN105037458A (en) * 2015-07-23 2015-11-11 诸城市浩天药业有限公司 Stevioside D glycoside crystal form A and preparation method and application thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017161985A1 (en) * 2016-03-24 2017-09-28 诸城市浩天药业有限公司 Crystal form of rebaudioside b and preparation process therefor and use thereof

Also Published As

Publication number Publication date
WO2017161985A1 (en) 2017-09-28
CN105646616B (en) 2019-08-06

Similar Documents

Publication Publication Date Title
JP5400766B2 (en) Polymorphs and amorphous forms of stevioside, methods of blending them, and methods of use
US11059843B2 (en) Stevioside M crystal form, preparation method therefor and use thereof
CN105037458A (en) Stevioside D glycoside crystal form A and preparation method and application thereof
CN107848979A (en) New crystal form of lenvatinib mesylate and preparation method thereof
CN105646616B (en) Steviol glycoside B crystal form G, its preparation method, food composition and application
TWI816791B (en) Salt, crystal form of fused ring pyrimidine compound and preparation method and application thereof
CN105693791B (en) Steviolbioside crystal form A, preparation method, food compositions and application
US20190382426A1 (en) Inclusion compound of 3' ,5'-cyclic diadenylic acid and manufacturing method thereof
CN103739639B (en) A kind of stevioside A glycoside crystal and its preparation method and application
CN103739640A (en) Stevioside A glycoside crystal and preparation method and application thereof
CN107188800B (en) Steviol crystal with crystal form A, its preparation method and application
CN105669795B (en) Stevioside C glycosides crystal forms V, preparation method, food compositions and application
CN105669794A (en) Rebaudioside B sodium salt crystal form A, and preparation method, food composition and application thereof
EP4095139A1 (en) Salt of arylaminopurine derivative, preparation method therefor and use thereof
CN107556350A (en) Rubusoside crystal, its preparation method, food compositions and application with crystal formation A forms
CN116903687A (en) A kind of steviol glycoside RA1G crystal form H4 and its preparation method and use
JP2023011874A (en) Cyclic-di-amp sodium salt crystal
CN118221753A (en) Stevioside RI glycoside crystal form A and preparation method and application thereof
CN116669735A (en) Crystal form of entrectinib and preparation method thereof
CN108424939A (en) A method of preparing steviol list glucose ester and its crystal form A form crystal
JP2006052213A (en) (2r,4r)-monatin potassium salt crystal

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
PE01 Entry into force of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Stevia B glycoside crystal form g, its preparation method, food composition and Application

Effective date of registration: 20210918

Granted publication date: 20190806

Pledgee: Bank of Weifang Zhucheng sub branch

Pledgor: ZHUCHENG HAOTIAN PHARM Co.,Ltd.

Registration number: Y2021980009630

PC01 Cancellation of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right

Date of cancellation: 20221122

Granted publication date: 20190806

Pledgee: Bank of Weifang Zhucheng sub branch

Pledgor: ZHUCHENG HAOTIAN PHARM Co.,Ltd.

Registration number: Y2021980009630

PE01 Entry into force of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Steviol B glycoside crystal form G, its preparation method, food composition, and application

Effective date of registration: 20230829

Granted publication date: 20190806

Pledgee: Bank of Weifang Zhucheng sub branch

Pledgor: ZHUCHENG HAOTIAN PHARM Co.,Ltd.

Registration number: Y2023980054328

PC01 Cancellation of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right

Granted publication date: 20190806

Pledgee: Bank of Weifang Zhucheng sub branch

Pledgor: ZHUCHENG HAOTIAN PHARM Co.,Ltd.

Registration number: Y2023980054328

PE01 Entry into force of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Stevia B glycoside crystal form g, its preparation method, food composition and Application

Granted publication date: 20190806

Pledgee: Bank of Weifang Zhucheng sub branch

Pledgor: ZHUCHENG HAOTIAN PHARM Co.,Ltd.

Registration number: Y2025980034843